Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Metrics to compare | PASG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPASGPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −5.4x | −0.5x | |
PEG Ratio | −0.01 | 0.02 | 0.00 | |
Price/Book | 0.4x | 3.5x | 2.6x | |
Price / LTM Sales | - | 229.9x | 3.2x | |
Upside (Analyst Target) | - | 167.9% | 42.0% | |
Fair Value Upside | Unlock | 8.1% | 6.6% | Unlock |